Cargando…

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Background: Independent of the SARS-CoV-2 pandemic, we developed a pilot program tracking productivity allowing research coordinators (RCs) to work from home. However, with the pandemic's onset all RCs were ordered to work from home starting March 25, 2020. Simultaneously, all in-person clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jenkins, Kimberly C, Zabor, Emily C, Mooney, Lindsey A.R., Gerds, Aaron T., O'Hop, Kerry, Guy, Makenzie, Kilbane, Megan, Pennell, Nathan A, Sekeres, Mikkael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2020
Materias:	903.Health Services Research-Malignant Conditions (Myeloid Disease)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338399/ http://dx.doi.org/10.1182/blood-2020-139937

Ejemplares similares

Home Care Program for Managing Oncology Patients during COVID-19 Pandemic. a Tertiary Referral Center Experience
por: Gmati, Giamal Edin, et al.
Publicado: (2020)

Acute Leukemia and COVID-19: The Johns Hopkins Experience
por: Miller, Karin Paige, et al.
Publicado: (2021)

Platform Incorporating Patient Navigation, Preparative Guidelines, and Hospital at Home May Improve COVID-19 Outcomes for Patients with Myeloid Malignancies
por: Ragon, Brittany Knick, et al.
Publicado: (2021)

Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program
por: Loke, (Justin) Ching Ting, et al.
Publicado: (2021)

GRUPO ABO E A SUSCETIBILIDADE A INFECÇÃO POR SARS-COV-2: UMA REVISÃO DE LITERATURA
por: Amorim, C.F., et al.
Publicado: (2020)

Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021
por: Ciambella, Silvia, et al.
Publicado: (2021)

Potential Benefits of a 6-Week Exercise and Mindfulness-Based Telehealth Training for HCT Survivors to Meet the Challenges of the COVID-19 Pandemic - a Feasibility Study
por: Ma, David, et al.
Publicado: (2021)

Covid-19 Infection in Hematological Malignancies: Registry Data from India
por: Jain, Arihant, et al.
Publicado: (2021)

Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia
por: Bradley, Terrence, et al.
Publicado: (2022)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub
por: Desai, Pinkal, et al.
Publicado: (2021)

Outcomes of COVID-19 Infection in Patients Receiving Ruxolitinib and Hypomethylating Agent Therapy
por: Nathan, Daniel I., et al.
Publicado: (2020)

COVID-19 and Hematologic Malignancies: Single Institution Analysis
por: Anusim, Nwabundo, et al.
Publicado: (2020)

Predictors of vascular disease in myelodysplastic syndromes
por: Faber, Mark G., et al.
Publicado: (2020)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
por: Kim, TaeHyung, et al.
Publicado: (2022)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

Increased body mass index is a risk factor for acute promyelocytic leukemia
por: Kashanian, Sarah M., et al.
Publicado: (2021)

Models of care for chronic myeloid leukemia patients during the COVID‐19 pandemic in the United Kingdom: Changes in patient attitudes to remote consultations and future implications
por: Duncan, Nicholas, et al.
Publicado: (2021)

DNA methylation analysis improves the prognostication of acute myeloid leukemia
por: Samimi, Hanie, et al.
Publicado: (2021)

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
por: Hernlund, Emma, et al.
Publicado: (2021)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia
por: Tian, Yun, et al.
Publicado: (2022)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
por: Cressman, Sonya, et al.
Publicado: (2020)

Fatal renal diseases among patients with hematological malignancies: A population‐based study
por: Li, Sen, et al.
Publicado: (2020)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
por: Galiègue‐Zouitina, Sylvie, et al.
Publicado: (2021)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
por: Carpenter, Lewis, et al.
Publicado: (2022)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, Vasiliki, et al.
Publicado: (2022)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Germline RUNX1 variants in paediatric patients in a French specialised centre
por: Liu, Cécile, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_04svlqf08d2joqi6af54pgrsdb